Newcastle University

Introduction

The Pro Vice Chancellor of the Faculty is responsible for overall management of Faculty business including setting and implementing strategy. This is done in conjunction with the Faculty Steering Group (FSG) comprising the Faculty Deans and Senior Support Officers and Faculty Executive Board (FEB) comprising FSG plus the heads of the academic units within the Faculty (research institutes and teaching focussed schools).

Research Interests

Information about my research interests can be found on the Institute of Cellular Medicine website.

• Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP. Hepatic Adducts, Circulating Antibodies, and Cytokine Polymorphisms in Patients with Diclofenac Hepatotoxicity. Hepatology 2004,39 5 1430-1440.
• Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45(4), 846-854.
• Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes. Gastroenterology 2007, 132(1), 272-281.
• Tilg H, Day CP. Management strategies in alcoholic liver disease. Nature Clinical Practice Gastroenterology and Hepatology 2007. , 4(1), 24-34.
• Day CP. From fat to inflammation. Gastroenterology 2006. , 130(1), 207-210.
• Day CP. Genes or environment to determine ALD and NAFLD. Liver International 2006. ,26 9 1021-1028.
• Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clinical Medicine 2006, 6(1), 19-25.
• Cortez-Pinto H, De Moura MC, Day CP. Non-alcoholic steatohepatitis: From cell biology to clinical practice. In: EASL Monothematic Conference. 2006, Estoril, Portugal: Journal of Hepatology, Elsevier BV.
• Tapirdamaz O, Pravica V, Metselaar HJ, Hansen B, Moons L, Van Meurs JBJ, Hutchinson IV, Shaw J, Agarwal K, Adams DH, Day CP, Kwekkeboom J. Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation. Gut 2006, 55(6), 863-868.
• Forrest EH, Evans CDJ, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut: an international journal of gastroenterology & hepatology 2005, 54(8), 1174-1179.
• Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005,54 7 987-993.
• Elabbadi N, Day CP, Gamouh A, Zyad A, Yeaman SJ. Relationship between the inhibition of phosphatidic acid phosphohydrolase-1 by oleate and oleoyl-CoA ester and its apparent translocation. Biochimie 2005,87 5 437-443.
• Day CP. Natural history of NAFLD: Remarkably benign in the absence of cirrhosis. Gastroenterology 2005. Maryland Heights, Missouri, USA:WB Saunders Co.,129 1 375-378.
• Stewart SF, Vidali M, Day CP, Albano E, Jones DEJ. Oxidative Stress as a Trigger for Cellular Immune Responses in Patients with Alcoholic Liver Disease. Hepatology 2004,39 1 197-203.
• Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and Hepatitis C Virus: Mechanisms and Significance for Hepatic and Extrahepatic Disease. Gastroenterology 2004. ,126 2 586-597.
• Vidali M, Stewart SF, Rolla R, Daly AK, Chen Y, Mottaran E, Jones DEJ, Leathart JB, Day CP, Albano E. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003,37 2 410-419.
• Stewart SF, Day CP. The management of alcoholic liver disease. Journal of Hepatology, Supplement 2003. ,38 1 S2-S13.
• Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. British Journal of Clinical Pharmacology 2001, 52(5), 489-499.
• Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. The Lancet 2001, 357(9256), 609-610.
• Day CP and James OFW. Steatohepatitis - a tale of two "hits"?. Gastroenterology 1998, 114, 842-845.
• Grove J, Brown AStJM, Daly AK, Bassendine MF, James OFW, Day CP. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: Effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998,8 4 335-342.
• Anstee QM, Day CP. A Lipid to Treat Non-Alcoholic Fatty Liver Disease – The Dawn of ‘Lipo-Rehabilitation’?. Journal of Hepatology 2012, 56(4), 987-989.
• Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metabolism Reviews 2012, 44(1), 116-126.
• Newsome PN, Allison ME, Andrews PA, Auzinger G, Day CP, Ferguson JW, Henriksen PA, Hubscher SG, Manley H, McKiernan PJ, Millson C, Mirza D, Neuberger JM, Oben J, Pollard S, Simpson KJ, Thorburn D, Tomlinson JW, Wyatt JS. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012, 61(4), 484-500.
• Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. Journal of Hepatology 2012, 56(1), 255-266.
• Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JBS, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. The SOD2 C₄₇T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology 2012, 56(2), 448-454.
• Iwata R, Baur K, Stieger B, Mertens JC, Daly AK, Frei P, Braun J, Vergopoulos A, Stickel F, Sabrane K, Martin IV, Schmitt J, Goetze O, Day CP, Mullhaupt B, Geier A, Swiss Hepatitis C Cohort Study Group. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clinical Science 2011, 120(7-8), 287-296.
• Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology 2011, 5(2), 253-263.
• Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochimica et Biophysica Acta: Molecular Basis of Disease 2011, 1812(11), 1557-1566.
• Anstee QM, Daly AK, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Seminars in Liver Disease 2011, 31(2), 128-146.
• Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease?. BMJ 2011, 343, d3897.
• de Alwis N, Aithal G, Bugianesi E, Leathart J, Hudson G, Pyle A, Mowbray C, Henderson E, Burt AD, Chinnery PF, Day CP. Mitochondrial DNA does not contribute to the heritability of non-alcoholic fatty liver disease. Mitochondrion 2011, 11(1), 234-235.
• Day CP. Non-alcoholic fatty liver disease: a massive problem. Clinical Medicine 2011, 11(2), 176-178.
• Ballestri S, Day CP, Daly AK. Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity. Gastroenterology 2011, 140(5), 1694-1695.
• Leavitt M, Burt AD, Hu W, Canty D, Gray M, Bray A, Harvey A, Day CP, Quinn AG. Recombinant lysosomal acid lipase normalizes liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesteryl ester storage disease. In: Journal of Hepatology: 46th Annual Meeting of the European Association for the Study of the Liver (EASL). 2011, Berlin, Germany: Elsevier BV.
• Hallsworth K, Fattakhova G, Hollingsworth K, Thoma C, Moore S, Taylor R, Day CP, Trenell MI. Resistance exercise improves liver lipid, fat oxidation and glucose control in adults with non-alchoholic fatty liver disease independent of weight loss. In: Journal of Hepatology: 46th Annual Meeting of the European Association for the Study of the Liver (EASL). 2011, Berlin, Germany: Elsevier BV.
• Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, Day CP, Trenell MI. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011, 60(9), 1278-1283.
• Targher G, Zoppini G, Day CP. Risk of all-cause and cardiovascular mortality in patients with chronic liver disease. Gut 2011, 60(11), 1602-1603.
• Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BHC, Carvajal A, Ibanez L, Yue Q-Y, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and class II alleles. Gastroenterology 2011, 141(1), 338-347.
• Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, Dongiovanni P, Fracanzani AL, Alterio A, Roviaro G, Daly AK, Fargion S, Day CP. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology 2011, 55(6), 1409-1414.
• Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J. The Natural History of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis or Cirrhosis: An International Collaborative Study. Hepatology 2011, 54(4), 1208-1216.
• Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, Lombard M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C, Burt A, Rosenberg W. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010, 59(9), 1245-1251.
• Day C. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Digestive Diseases 2010, 28(1), 255-260.
• Seth D, Daly A, Haber P, Day C. Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology 2010, 51(4), 1463-1465.
• Fontana R, Seeff L, Andrade R, Björnsson E, Day C, Serrano J, Hoofnagle J. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop. Hepatology 2010, 52(2), 730-742.
• Day CP, Rau KM, Hung MC. [abstract] Selective breast tumor growth suppression mediated by the enhanced breast cancer-specific promoter. Molecular Therapy 2004, 9(S113), abstract no. 295.
• Stewart SF, Jones DEJ, Vidali M, Haugk B, Burt AD, Albano E, Day CP. Correlation between anti-CYP2E1 titre and lymphocyte infiltration in ALD - An autoimmune disease in some patients?. In: Journal of Hepatology: 39th Annual Meeting of the European Association for the Study of the Liver. 2004, Berlin, Germany: Elsevier BV.
• Day C. Genetic susceptibility to alcoholic liver disease. In: Toxicology: BTS 2004 Annual Congress. 2004, Edinburgh, UK: Elsevier Ireland Ltd.
• Mirzaa G, Dodge NN, Glass I, Day C, Gripp K, Nicholson L, Straub V, Voit T, Dobyns WB. Megalencephaly and perisylvian polymicrogyria with postaxial polydactyly and hydrocephalus: a rare brain malformation syndrome associated with mental retardation and seizures. Neuropediatrics 2004, 35(6), 353-359.
• Makino K, Day CP, Wang SC, Li YM, Hung MC. Upregulation of IKK alpha/IKK beta by integrin-linked kinase is required for HER2/neu-induced NF-kappa B antiapoptotic pathway (vol 23, pg 3883, 2004). Oncogene 2004, 23(54), 8857-8857.
• Saksena S, Leathart JB, Daly AK, Day CP. Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease. In: Journal of Hepatology: 38th Annual Meeting of the European Association for the Study of the Liver. 2003, Istanbul, Turkey: Elsevier BV.
• Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Oxidative stress is an independent risk factor for the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis. In: Hepatology: 54th Annual Meeting of the American Association for the Study of Liver Disease. 2003, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
• Aithal GP, Leathart JB, Dang TS, Day CP, Daly AK. Association of udp-glucuronosyltransferase (UGT) 2B7 genotype with diclofenac-induced hepatotoxicity. In: Hepatology: 53rd Annual Meeting of the Association for the Study of Liver Diseases. 2002, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
• Day C. CD14 promoter polymorphism associated with risk of NASH. Journal of Hepatology 2002, 36(s1), 21.
• Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. British Journal of Clinical Pharmacology 2002, 53(4), 408-409.
• Day C, Leathart J, Daly A. Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease. Journal of Hepatology 2002, 36(s1), 16 abstract no. 41.
• Mottaran E, Stewart SF, Rolla R, Vay D, Cipriani V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radical Biology & Medicine 2002, 32(1), 38-45.
• Day CP. NASH-Related liver failure: One hit too many?. American Journal of Gastroenterology 2002, 97(8), 1872-1874.
• Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?. Gut 2002, 50(5), 585-588.
• Day CP. Non-alcoholic steatohepatitis (NASH): why biopsy? - Author's reply. Gut 2002, 51(6), 898-899.
• Day CP, Saksena S. Non-alcoholic steatohepatitis: Definitions and pathogenesis. In: Journal of Gastroenterology and Hepatology. 2002, Wiley-Blackwell Publishing Asia.
• Day CP. Pathogenesis of steatohepatitis. Best Practice & Research: Clinical Gastroenterology 2002, 16(5), 663-678.
• Daly AK, Day CP, Donaldson PT. Polymorphisms in immunoregulatory genes: towards individualised immunosupressive therapy?. American Journal of PharmacoGenomics 2002, 2(1), 13-23.
• Donaldson PT, Day CP. Predictive Value of Cytokine Polymorphisms for Liver Disease. In: Cytokines in Liver Injury and Repair. 2002, Hannover, Germany: Kluwer Academic Press.
• Elabbadi N, Day CP, Virden R, Yeaman SJ. Regulation of phosphatidic acid phosphohydrolase 1 by fatty acids. Lipids 2002, 37(1), 69-73.
• Kwong KY, Zou YY, Day CP, Hung MC. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene 2002, 21(54), 8340-8346.
• Stewart SF, Leathart JB, Chen Y, Daly AK, Rolla R, Vay D, Mottaran E, Vidali M, Albano E, Day CP. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology 2002, 36(6), 1355-1360.
• Stewart SF, Daly AK, Chen Y, Leathart JB, Jones DEJ, Rolla R, Vay D, Mottaran E, Vidali M, Albano E, Day CP. A polymorphism in CTLA-4 is associated with the presence of anti-CYP2E1 antibody titres in patients with alcoholic liver disease. Journal of Hepatology 2001, 34(1), 200.
• Stewart S, Jones D, Day CP. Alcoholic liver disease: New insights into mechanisms and preventative strategies. Trends in Molecular Medicine 2001, 7(9), 408-413.
• Day CP. Apoptosis and acute alcoholic hepatitis: a novel therapeutic target?. Journal of Hepatology 2001, 34(2), 330-333.
• Day CP. Apoptosis in alcoholic hepatitis: A novel therapeutic target?. Journal of Hepatology 2001, 34(2), 330-333.
• Aithal GP, Day CP, Leathart JBS, Daly AK, Hudson M. Association of a 5'-flanking region polymorphism in the interleukin-4 gene with Crohn’s disease in a British population. Genes and Immunity 2001, 2, 44-47.
• Aithal GP, Day CP, Leathart J, Daly AK, Hudson M. Association of a polymorphism in the interleukin-4 gene with Crohn’s diseases. Genes and Immunity 2001, 2, 44-47.
• Day CP. Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis. Gut 2001, 49(6), 750-751.
• Benitez J, Lorite MJ, Burt AD, Day CP, Geerts A. Identification of phospholipase D gene products in activated rat hepatic stellate cells - Stimulation by PDGF and nucleotides. Journal of Hepatology 2001, 34(1), 90-90.
• Stewart SF, Day CP. Liver disorder and the HFE locus. QJM - Monthly Journal of the Association of Physicians 2001, 94(9), 453-456.
• Leathart JB, Day CP, Daly AK. No association between functional SNPs in the endotoxin receptors CD14 and TLR4 and alcoholic liver disease (ALD): Is endotoxin important in the pathogenesis of aid in humans?. In: Hepatology. 2001, John Wiley & Sons, Inc.
• Benitez J, Lorite MJ, Burt AD, Day CP, Thompson MG. Nucleotides stimulate phospholipase D activity in hepatic stellate cells: evidence for the involvement of a single nucleotide receptor, protein kinase C and a pertussis toxin insensitive guanine nucleotide binding protein. In: Cells of the Hepatic Sinusoid: 10th International Conference. 2001, Southampton, UK: Kupffer Cell Foundation.
• Burt AD, Day CP. Pathophysiology of the Liver. In: MacSween, RNM; Burt, AD; Portman, BC; Ishak, KG; Scheur, PJ; Anthony, PP, ed. Pathology of the Liver. London: Churchill Livingstone, 2001, pp.67-106.
• Agarwal K, Daly AK, Leathart JB, Hudson M, Day CP. Polymorphisms of immunoregulatory genes: A step towards individually tailored immunosuppression?. In: British Association for the Study of the Liver Meeting. 2001, University of Southampton: BMJ Publishing Group Ltd.
• Vidali M, Rolla R, Stewart SF, Mottaran E, Vay D, Sartori M, Rigamonti C, Day CP, Albano E. Prevalence of auto-antibodies against cytochrome in alcoholic liver disease. In: Journal of Hepatology. 2001, Elsevier BV.
• Lorite MJ, Bevitt DJ, Benitez J, McKie N, Day CP. Regulation of ADAMS family members in hepatic stellate cells by soluble growth factors: Evidence for their role in hepatic fibrogenesis. In: Hepatology. 2001.
• Vidali M, Stewart SF, Rolla R, Daly AK, Chen YN, Mottaran E, Vay D, Cipriani VE, Jones DE, Leathart JB, Day CP, Albano E. Role of CTLA-4 genetic polymorphism in the development of anti- cytochrome P4502EI auto-antibodies during alcoholic liver disease. Hepatology 2001, 34(4), 312.
• Jacob J, Saksena S, Leathart JB, James O, Daly AK, Day CP. Single nucleotide polymorphisms (SNPs) associated with genetic susceptibility to NASH/NAFLD and ALD: Same again please!. In: British Association for the Study of the Liver Meeting. 2001, Royal Free Hospital, London: John Wiley & Sons.
• Lorite MJ, Bevitt DJ, Benitez J, McKie N, Day CP. The ADAMs: A modular protein family with metalloproteinase and proteoglycan degrading activities expressed by the hepatic stellate cell. In: British Association for the Study of the Liver Meeting. 2001, University of Southampton: BMJ Publishing Group Ltd.
• Day CP, Daly AK. The genetic basis for non-alcoholic and alcoholic steatohepatitis. In: 121st Falk Symposium: Steatohepatitis (NASH and ASH). 2001, The Hague, Netherlands: Springer.
• Rolla R, Stewart SF, Mottaran E, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E. Alcohol-induced oxidative stress contributes to development of immune reactions associated with alcoholic liver disease. In: HEPATOLOGY. 2000.
• Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: A useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. Journal of Hepatology 2000, 33(6), 949-952.
• Aithal PG, Rawlins MD, Day CP. Evaluation of the clinical diagnostic scale in the assessment of suspected hepatotoxic adverse drug reaction (ADR) reports. In: GUT. 2000.
• Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000, 46(4), 540-545.
• Day CP, Hudson M, Talbot D, Manas D. Monotherapy with mycophenolate mofetil (MMF): Good for the kidneys bad for the liver. In: JOURNAL OF HEPATOLOGY. 2000.
• Lorite MJ, Benitez J, Burt AD, Day CP, Thompson MG. Nucleotides stimulate protein synthesis in hepatic stellate cells: Potential role of phospholipase D - Mediated lipid hydrolysis. In: JOURNAL OF PATHOLOGY. 2000.
• Aithal PG, Daly AK, Chen Y, Day CP. Promoter polymorphisims of IL-10 and IL-4 predict risk of diclofenac-induced hepatitis. In: JOURNAL OF HEPATOLOGY. 2000.
• Aithal GP, Daly AK, Leathart J, Yuanneng CP, Day CP. Promoter polymorphisms of interleukin-10 (IL-10) and interleukin-4 (IL-4) predict the risk of diclofenac-induced hepatotoxicity. In: GASTROENTEROLOGY. 2000.
• Stewart SF, Daly AK, Chen YN, Leathart JB, Rolla R, Vay D, Mottaran E, Vidali M, Albano E, Day CP. Susceptibility to alcoholic liver disease is due to genetically determined differences in the immune response to acetaldehyde adducts. In: HEPATOLOGY. 2000.
• Rutter MD, Agarwal S, Record CO, Day CP, James OFW, Hudson M. Terlipressin for hepatorenal impairment in alcoholic hepatitis. In: Journal of Hepatology. 2000.
• Day CP. Who gets alcoholic liver disease: Nature or nurture?. Journal of the Royal College of Physicians of London 2000, 34(6), 557-562.
• Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353(9154), 717-719.